To provide advice on the use of mifepristone for medical abortion.
All health professionals providing gynaecological care, and patients.
The evidence was reviewed by the Women’s Health Committee RANZCOG, and applied to local factors relating to Australia and New Zealand.
This statement was first developed by Women’s Health Committee in November 2007 and reviewed in March 2019.
The development and review of this statement was funded by RANZCOG.